使用血管活性药物的危重患者肱动脉-桡动脉压力梯度:一项前瞻性观察研究
结果显示18.4%的患者存在大于11 mm Hg的临床显著肱-桡无创动脉压梯度。存在显著梯度者去甲肾上腺素等效剂量更高(0.23 vs 0.10 µg/kg/min)、SOFA评分更高(11 vs 10)、毛细血管再充盈时间延长(3.0 vs 2.5 s)、乳酸更高(2.7 vs 1.3 mmol/L)。多因素分析仅血管活性药物剂量与显著梯度独立相关。显著梯度患者ICU死亡率更高(48.0% vs 30.1%)。
要点
- 303例使用血管活性药物并带桡动脉导管的ICU患者中,18.4%存在大于11 mm Hg的肱-桡无创动脉压梯度。
- 与无显著梯度者相比,有显著梯度者去甲肾上腺素等效剂量更高(0.23 vs 0.10 µg/kg/min),SOFA评分更高(11 vs 10)。
- 显著梯度者毛细血管再充盈时间延长(3.0 vs 2.5 s),乳酸浓度更高(2.7 vs 1.3 mmol/L)。
- 多因素分析中仅血管活性药物剂量与NIBR-APG>11 mm Hg独立相关(比值比1.68;95% CI 1.12-2.52)。
- 存在显著梯度者ICU死亡率为48.0%,高于无显著梯度者的30.1%。
适用人群与场景
- 303例患者中49.5%为外科收治,33.3%为脓毒性休克。
诊断标准与关键阈值
- NIBR-APG定义为无创肱动脉MAP与有创桡动脉MAP差值,大于11 mm Hg判定为临床显著。
- 有创桡动脉MAP与无创肱动脉MAP各测量两次后取平均值。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 存在NIBR-APG>11 mm Hg者病情更重:SOFA评分更高(11 vs 10)、乳酸浓度更高(2.7 vs 1.3 mmol/L)、毛细血管再充盈时间延长(3.0 vs 2.5 s)。
- 显著梯度患者ICU死亡率达48.0%,高于无显著梯度者的30.1%。
- 临床显著NIBR-APG与更高血管活性药物剂量独立相关(比值比1.68;95% CI 1.12-2.52)。
研究设计与关键结果
- 显著梯度者去甲肾上腺素等效剂量更高(0.23 vs 0.10 µg/kg/min),SOFA评分11 vs 10,毛细血管再充盈时间3.0 vs 2.5 s,乳酸2.7 vs 1.3 mmol/L。
- 多变量分析仅血管活性药物剂量与NIBR-APG>11 mm Hg独立相关(比值比1.68;95% CI 1.12-2.52)。
- ICU死亡率:显著梯度者48.0%,无显著梯度者30.1%。
证据类型、等级与局限
- 证据类型:前瞻性、多中心、观察性研究。
- 局限:原文未提及。
- 设计本身为观察性研究,无法确立因果关系。
对床旁实践的改变
- 对使用血管活性药物尤其剂量较高的ICU患者,需警惕桡动脉有创压可能低估中心动脉压,可考虑用无创肱动脉压对照。
- 发现肱-桡无创动脉压梯度>11 mm Hg时,提示患者血管活性药物需求更高、病情更重、死亡风险增加。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the incidence of a significant noninvasive brachial-to-radial arterial pressure gradient (NIBR-APG) and its clinical associations in critically ill patients receiving vasoactive agents.
DESIGN: Prospective, multicenter, observational study.
SETTING: Thirteen ICUs in Poland.
PATIENTS: Adult ICU patients with radial arterial catheters receiving vasoactive agents hospitalized between April 2025 and July 2025.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Invasive radial mean arterial pressure (MAP) and noninvasive brachial MAP were measured twice and averaged. A NIBR-APG greater than 11 mm Hg was predefined as clinically significant. Baseline characteristics, hemodynamic variables, and outcomes were recorded. Among 303 patients, 49.5% were surgical admissions and 33.3% had septic shock. The median NIBR-APG was 4.5 mm Hg (interquartile range, 0.0-10.0 mm Hg). Fifty-six patients (18.4%) exhibited a NIBR-APG greater than 11 mm Hg. Compared with patients without a significant gradient, these patients received higher norepinephrine-equivalent doses (0.23 vs. 0.10 µg/kg/min), had higher Sequential Organ Failure Assessment scores (11 vs. 10), prolonged capillary refill time (3.0 vs. 2.5 s), and higher lactate concentrations (2.7 vs. 1.3 mmol/L). In multivariable analysis, only vasoactive drug dose was independently associated with NIBR-APG greater than 11 mm Hg (odds ratio, 1.68; 95% CI, 1.12-2.52). ICU mortality was higher in patients with significant gradients (48.0% vs. 30.1%).
CONCLUSIONS: Nearly one in five critically ill patients receiving vasoactive agents demonstrated a clinically significant NIBR-APG. The presence of this gradient was independently associated with higher vasoactive drug requirements and was accompanied by greater illness severity and higher ICU mortality.
参考来源
- Putowski, Gawda, Czarnik, et al. Brachial-to-Radial Pressure Gradient in Critically Ill Patients Treated With Vasoactive Agents: A Prospective Observational Study. Crit Care Med. 2026. PMID: 42919451. doi:10.1097/CCM.0000000000007391
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。